DiamiR Biosciences has obtained Clinical Laboratory Evaluation Program approval from the New York State Department of Health for its APOE Genotyping test, a molecular diagnostic that identifies genetic variants linked to late-onset Alzheimer’s disease. The clearance allows the company’s CLIA-certified, CAP-accredited laboratory to process blood, saliva, buccal-swab and tissue samples for licensed health-care providers in New York and across the United States. The test expands access to a tool used in risk assessment, clinical-trial enrollment and potential treatment planning for neurodegenerative conditions such as mild cognitive impairment and Alzheimer’s. The regulatory milestone also broadens the diagnostic portfolio of Aptorum Group, which entered into an all-stock agreement on 14 July to acquire DiamiR; the merger is slated to close in the fourth quarter, subject to shareholder approval.